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Survival continues to increase in chronic lymphocytic leukae-
mia: a population-based analysis among 20 468 patients diag-
nosed in the Netherlands between 1989 and 2016
Chronic lymphocytic leukaemia (CLL) is the most frequently
diagnosed and prevalent form of leukaemia among adults in
Western countries (Brenner et al., 2008; Kristinsson et al.,
2009; Van den Broek et al., 2012). The gradual increase in
life expectancy in Western countries over the past decades is
one of the contributing factors that brought about the
increasing incidence and prevalence of CLL, particularly
among the elderly (Van den Broek et al., 2012). Also, diag-
nostic procedures have been refined, leading to increased
detection of CLL at an earlier stage (Bennett et al., 1989).
Besides, the therapeutic armamentarium of CLL has rapidly
evolved with improvements in supportive care and risk-
adapted therapy, and, more importantly, the advent of pur-
ine analogues, anti-CD20 agents, kinase inhibitors, and pro-
apoptotic agents (Hallek, 2017). Despite the significant
advances in diagnosis, prognostication, and treatment of CLL
over the past decades, it is mostly unknown how these
advances have impacted the survival of patients with CLL at
the population level, especially among contemporarily diag-
nosed patients.
At present, large, representative population-based studies
on this issue are scant and mostly do not encompass patients
managed with first- and second-generation anti-CD20 agents,
kinase inhibitors, and pro-apoptotic agents (Brenner et al.,
2008; Kristinsson et al., 2009; Thygesen et al., 2009; Van den
Broek et al., 2012). Therefore, the aim of this contemporary,
nationwide, population-based study was to assess trends in
short-term and long-term excess mortality among patients
with CLL diagnosed during a 28-year period in the Nether-
lands.
We selected all patients with CLL diagnosed between Jan-
uary 1, 1989 and December 31, 2016 – with follow-up for
survival until January 1, 2019 – from the nationwide popula-
tion-based Netherlands Cancer Registry (NCR), using Inter-
national Classification of Diseases for Oncology morphology
code 9823. Details about the registry are provided in the
Supporting Information (Data S1).
Relative survival rates (RSRs) were calculated for four cal-
endar periods of diagnosis (1989–1995, 1996–2002, 2003–
2008 and 2009–2016) and four age categories at diagnosis
(18–59, 60–69, 70–79 and ≥80 years) and measured from the
time of diagnosis to death, emigration, or end of follow-up,
whichever occurred first. Relative survival (RS) is the overall
survival (OS) in the patient cohort divided by the expected
OS of an equivalent group from the general population,
matched to the patient group by age, sex, and period (Dick-
man & Adami, 2006). Multivariable evaluation of RS using
Poisson regression was performed to assess linear trends in
RS over time and the relative excess risk of mortality. A
P < 005 indicated statistical significance. Further details
about the statistical analyses are provided in Data S1. The
Privacy Review Board of the NCR approved the use of
anonymous data for this study.
Baseline characteristics of 20 468 patients with CLL (me-
dian age, 69 years; range 21–101 years; 61% males) included
in this study are presented in Table SI. The overall age-stan-
dardised incidence rate (ASR) of CLL gradually increased
over time, but remained comparatively steady from 2003
onwards (Table SI and Figure S1). Throughout the entire
study period, a consistent male predominance was observed
(Table SI and Figure S1). The age-specific incidence rises
sharply with older age (Figure S2).
Patients across all age groups experienced ongoing excess
mortality – as compared to the general population – in all
calendar periods studied (Figure 1). Nevertheless, RSRs
improved with each calendar period across all age groups.
The multivariable model confirmed an improvement of RS
across all age groups in the most recent calendar period
(2009–2016) – as compared to the calendar period 2003–
2008 – and showed a poor prognostic effect of male sex (up
to age 80) and a previous malignancy before CLL diagnosis
(Table I).
In this contemporary, nationwide, population-based study,
we demonstrated that the overall ASR of CLL gradually
increased until it remained comparatively steady from 2003
onwards. Similar trends were observed in Denmark and Swe-
den (Kristinsson et al., 2009; Thygesen et al., 2009). The ini-
tial increase can probably be explained by several factors.
First, general practitioners and hospital-based physicians
might nowadays be more diligent in requesting routine blood
tests, potentially leading to the enhanced detection of early,
asymptomatic CLL. Furthermore, the incidence of CLL might
be overestimated, because most patients diagnosed with Rai
stage 0 or I before 2008 can be reclassified into monoclonal
B-cell leukaemia according to the most recent diagnostic cri-
teria (Hallek et al., 2008). On the other hand, the incidence
might be underestimated in these earlier calendar periods,
because CLL is most frequently diagnosed by flow cytometry
correspondence
ª 2020 British Society for Haematology and John Wiley & Sons Ltd doi: 10.1111/bjh.16397
Calender period
RSR
1989–1995 1995–2002 2009–2016 P for
trend*RSR (in%) with 95% CI
5–year 80 (77–84) 88 (86–90) 90 (88–92) 95 (94–96) <0·001
10–year 59 (54–63) 71 (68–74) 80 (77–82) 84 (79–88) <0·001
(A) (B)
18–59 years 60–69 years
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Years from diagnosis
Calender period
1989–1995 1995–2002 2003–2008 2009–2016 P for
trend*RSR (in%) with 95% CI
72 (68–75) 81 (78–83) 86 (84–88) 91 (89–93) <0·001
51 (48–55) 62 (58–65) 70 (67–73) 81 (77–85) <0·001
Calender period
RSR
1989–1995 1995–2002 2003–2008 2009–2016 P for
trend*RSR (in%) with 95% CI
5–year 64 (61–68) 71 (68–74) 81 (78–84) 85 (83–88) <0·001
10–year 42 (37–47) 50 (46–54) 64 (60–68) 71 (64–78) <0·001
Years from diagnosis
Calender period
1989–1995 1995–2002 2003–2008 2009–2016 P for
trend*RSR (in%) with 95% CI
52 (46–59) 53 (47–60) 69 (63–75) 77 (71–82) <0·001
32 (23–43) 51 (40–64) 42 (34–52) 56 (37–79) <0·001
(C) (D)
70–79 years ≥80 years
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and most cancer registries primarily rely on pathology
reports for case notification (Zent et al., 2001). Thus,
although the NCR does not solely rely on pathology reports
for case notification, the ascertainment of early, asymp-
tomatic CLL might be underestimated in the NCR in earlier
periods (i.e. between 1989 and 2003).
A noteworthy finding of our study was that RS of CLL
improved continuously over the calendar periods studied.
This finding is congruent with results observed in the paucity
of prior population-based studies from the United States
(1980–2011), Germany (1997–2011), Denmark (1943–2003)
and Sweden (1973–2003). Encouragingly enough, RSRs in
the most recent calendar period of our study (2009–2016)
surpassed those reported in the aforementioned studies
(Brenner et al., 2008; Kristinsson et al., 2009; Thygesen et al.,
2009; Pulte et al., 2016). Advances in supportive care (i.e.
transfusions, growth factors, and antibiotics) and therapy are
key factors that contributed to the improvement in RS over
time. However, a normalised plateau in RS has not been
reached, suggesting ongoing excess mortality for the overall
patient population. Recent progress with kinase inhibitors
(e.g. ibrutinib) and pro-apoptotic agents (e.g. venetoclax)
might further reduce excess mortality in CLL. However, the
benefit of these novel agents cannot be entirely objectivated
in this study, since these modalities were not widely imple-
mented for routine application in CLL in the Netherlands
during the study period.
The main strengths of our study include the use of a
nationwide population-based cancer registry with compre-
hensive data available for individual patients. Limitations of
our study include a lack of information on cytogenetic and
molecular diagnostics and treatment throughout most of the
registry. Therefore, it is not possible to correct for changes in
the classification of CLL over time.
In summary, in this large, contemporary, nationwide pop-
ulation-based study, RS improved significantly over time
among patients with CLL across all age groups. The current
study provides a benchmark for future research to evaluate
the impact of a broader application of kinase inhibitors and
anti-apoptotic agents on RS.
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Table I. Excess mortality ratio during the first 10 years after chronic
lymphocytic leukaemia diagnosis across different age groups.
Age at diagnosis Covariate EMR* 95% CI P†
18–59 Period of diagnosis
1989–1995 230 189–280 <0001
1996–2002 147 121–179 <0001
2003–2008 1 (ref)
2009–2016 062 048–081 <0001
Female sex 065 055–077 <0001
Previous malignancy 165 121–225 0002
60–69 Period of diagnosis
1989–1995 200 171–235 <0001
1996–2002 140 119–165 <0001
2003–2008 1 (ref)
2009–2016 059 048–072 <0001
Female sex 060 052–068 <0001
Previous malignancy 140 114–172 0001
70–79 Period of diagnosis
1989–1995 213 180–251 <0001
1996–2002 159 135–188 <0001
2003–2008 1 (ref)
2009–2016 072 060–087 0001
Female sex 059 052–067 <0001
Previous malignancy 194 167–225 <0001
≥80 Period of diagnosis
1989–1995 188 150–234 <0001
1996–2002 144 114–182 0002
2003–2008 1 (ref)
2009–2016 058 044–076 <0001
Female sex 098 083–116 0830
Previous malignancy 149 120–184 <0001
EMR, excess mortality ratio; CI, confidence interval.
*All covariates are simultaneously adjusted.
†P-values are compared with the reference category.
Fig 1. Relative survival of patients with chronic lymphocytic leukaemia diagnosed in the Netherlands according to calendar period of diagnosis
and age at diagnosis, 1989–2016. Relative survival is shown for four calendar periods according to the following four age categories: (A) 18–59,
(B) 60–69, (C) 70–79, and (D) ≥80 years. The tables present the projected 5- and 10-year relative survival rates (RSRs) with 95% confidence
intervals (CIs) according to calendar period of diagnosis for the four age categories. *, P-value for likelihood ratio test assessing linear trends
between the first and last calendar period. RSRs for patients aged ≥80 years were truncated at 10 years, since comparatively few patients in this
age group were alive 10 years after their diagnosis.
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Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Figure S1. Age-specific incidence rates of patients with
chronic lymphocytic leukaemia in the Netherlands according
to age, 1989–2016. Incidence rates are presented per 100 000
person-years and shown according to the following sexes:
(A) males and females together, (B) males alone, and (C)
females alone.
Figure S2. Age-specific incidence rates of patients with
chronic lymphocytic leukaemia in the Netherlands per quin-
quennial years of age, 2003–2016. Incidence rates are pre-
sented per 100 000 person-years and shown according to sex.
The period of 2003–2016 was chosen, as the incidence of
CLL in the Netherlands remained comparatively steady as
from 2003.
Table SI. Patient characteristics.
Data S1. Supplemental methods.
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